On Tuesday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Cytori Therapeutics Inc (NASDAQ:CYTX), Frontline Ltd (NYSE:FRO), Genetic Technologies Limited (ADR) (NASDAQ:GENE), Triangle Petroleum Corporation (NYSEMKT:TPLM)
Cytori Therapeutics Inc (NASDAQ:CYTX)’s shares dwindled 3.65%, and closed at $1.32. The stock has price to sale ratio of 17.96, however, price to cash ratio is 16.81. With recent decline, the year-to-date (YTD) performance reflected a 169.39% gain above last year. During the past month the stocks gain 180.85%, bringing three-month performance to 149.06% and six-month performance to 24.53%. The mean recommendation of analysts for this stock is 2.00. (where 1=Buy, 5=Sale).
Cytori Therapeutics, Inc., a cell therapy company, develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. It primarily provides the Celution System, a tissue processing system that automates the process of digesting fat tissue, releasing the ADRCs. The company also offers the StemSource Cell Bank, a suite of products to allow hospitals or tissue banks to cryopreserve adipose-derived stem and regenerative cells; and StemSource 900/MB, a research laboratory equipment. Its products also comprise Celution 800 System that has CE Mark approval for certain soft tissue procedures, such as breast reconstruction, tissue ischemia, deficiency or injury of skin, fat, and muscle and fascia, in addition to soft tissue wounds or fistulae associated with trauma, diabetes, ischemia, and radiation injury.
Frontline Ltd (NYSE:FRO) declined -3.63%, and closed at $2.39. The stock volatility for the week is 4.27%, while for the month remained 4.99%. The company holds consensus target price of $2.13.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -1.55diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -121.70% and Annual EPS growth for the past 5 years is considered as -17.70%.
The mean recommendation of analysts for this stock is 3.40. (where 1=Buy, 5=Sale).
Frontline Ltd., through its subsidiaries, is engaged in the ownership and operation of oil tankers and oil/bulk/ore carriers. The company provides seaborne transportation of crude oil and oil products, in addition to raw materials, such as coal and iron ore. Its very large crude carriers (VLCCs) primarily transport crude oil from the Middle East Gulf to the Far East, Northern Europe, the Caribbean, and the Louisiana Offshore Oil Port, in addition to Suezmax tankers trade in the Atlantic Basin, the Middle East, and Southeast Asia. As of December 31, 2013, the company’s tanker fleet comprised of 33 vessels, counting 23 VLCCs and 10 Suezmax tankers. It is also involved in the charter, purchase, and sale of vessels. The company has operations in the Bahamas, Bermuda, the Cayman Islands, India, the Isle of Man, Liberia, Norway, the United Kingdom, and Singapore. Frontline Ltd. was founded in 1948 and is based in Hamilton, Bermuda.
Genetic Technologies Limited (ADR) (NASDAQ:GENE), dipped -3.60%, and closed at $4.29. The company holds the market capitalization of $53.63M. For the last twelve months, the stock was able to keep return on equity at -311.60%, while return on assets at -184.50%, in response to its return on investment at -232.40%. Its 20-day moving average declined -30.11%, above 50-day moving average of 4.90%, above 200-day moving average of 22.93% from the latest market price of $ 4.29. The mean recommendation of analysts for this stock is 3.00.(where 1=Buy, 5=Sale).
Genetic Technologies Limited operates as a life science company, specializing in the fields of genetics and genomics primarily in Australia. The company provides genetic testing services to human beings for disease susceptibility, parentage, individual identity, forensics, and sports performance; animals, such as dogs, horses, birds, alpacas, exotics, and zoo animals for parentage, pedigree, traits, and disease susceptibility; and plants for traits and disease susceptibility. It also offers canine reproductive services, in addition to involves in licensing its non-coding DNA patents. In addition, the company offers BREVAGen, a diagnostic test that informs clinicians and patients about individual, non-familial, sporadic risk of breast cancer for women where a breast biopsy outcome is indeterminate. The company was formerly known as Duketon Goldfields N.L. and changed its name to Genetic Technologies Limited in August 2000. Genetic Technologies Limited was incorporated in 1987 and is based in Fitzroy, Australia.
Triangle Petroleum Corporation (NYSEMKT:TPLM)), dropped -3.48%, and closed at $4.72. The company has the market capitalization of $374.63M. The beta value of the stock is 2.08. On the other hand the stock’s volatility for the week is 5.35%, and for the month is 6.25%. The stock’s price to book ratio is 0.75, however price to sale ratio is 0.72. Analyst’s mean recommendation regarding this stock is 2.60. (where 1=Buy, 5=Sale).
Triangle Petroleum Corporation is engaged in the attainment, exploration, development, and production of unconventional shale oil and natural gas resources in the Bakken Shale and Three Forks formations in the Williston Basin of North Dakota and Montana. As of January 31, 2014, the company held leasehold interests in about 94,000 net acres in McKenzie and Williams Counties of North Dakota, and Sheridan and Roosevelt Counties of Montana. It also holds leasehold interest in Maritimes Basin located in Nova Scotia, Canada. In addition, the company offers hydraulic pressure pumping and complementary well completion services to oil and natural gas exploration and production companies in the Williston Basin of North Dakota and Montana. The company was formerly known as Peloton Resources Inc. and changed its name to Triangle Petroleum Corporation in May 2005. Triangle Petroleum Corporation was incorporated in 2003 and is headquartered in Denver, Colorado.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
